Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Debt (2016 - 2017)

Historic Non-Current Debt for Protalix BioTherapeutics (PLX) over the last 6 years, with Q3 2017 value amounting to $4.3 million.

  • Protalix BioTherapeutics' Non-Current Debt changed 0.0% to $4.3 million in Q3 2017 from the same period last year, while for Sep 2017 it was $4.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $4.3 million for FY2016, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2017, Protalix BioTherapeutics' Non-Current Debt is $4.3 million, which was down 0.0% from $4.3 million recorded in Q2 2017.
  • In the past 5 years, Protalix BioTherapeutics' Non-Current Debt registered a high of $4.3 million during Q4 2015, and its lowest value of $376000.0 during Q2 2013.
  • For the 4-year period, Protalix BioTherapeutics' Non-Current Debt averaged around $3.6 million, with its median value being $4.3 million (2015).
  • In the last 5 years, Protalix BioTherapeutics' Non-Current Debt plummeted by 9196.58% in 2013 and then changed by 0.0% in 2016.
  • Quarter analysis of 4 years shows Protalix BioTherapeutics' Non-Current Debt stood at $2.4 million in 2013, then surged by 81.4% to $4.3 million in 2015, then changed by 0.0% to $4.3 million in 2016, then changed by 0.0% to $4.3 million in 2017.
  • Its Non-Current Debt was $4.3 million in Q3 2017, compared to $4.3 million in Q2 2017 and $4.3 million in Q1 2017.